Related Experiment Video

Updated: Apr 30, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

27.4K

Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin

K P Bliden, A Singla, M G Gesheff

  • 1Paul A. Gurbel, MD, Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, 2401 W. Belvedere Ave, Baltimore, MD 21215, USA, Tel.: +1 410 601 9600, Fax: +1 410 601 9601,

Thrombosis and Haemostasis
|April 26, 2014
PubMed

Insights

Statin therapy, combined with aspirin, reduces inflammation and blood clot strength in coronary artery disease patients. Higher statin doses correlate with lower thromboxane (Tx) levels, suggesting optimized dosing can reduce thrombotic risk.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Coronary artery disease (CAD) management involves aspirin and statin therapy.
  • The interplay between statin use, thromboxane (Tx) generation, and blood thrombogenicity in CAD patients remains underexplored.
  • Urinary 11-dehydro (dh) TxB2 serves as a marker for in vivo Tx generation and inflammation.

Purpose of the Study:

  • To investigate the relationship between statin therapy, inflammation (measured by urinary 11-dh TxB2), and blood thrombogenicity in patients with suspected CAD on aspirin.
  • To determine if statin dose influences Tx generation and thrombotic risk.

Main Methods:

  • Urinary 11-dh TxB2 levels were measured in 281 patients with suspected CAD receiving daily aspirin.
  • Blood thrombogenicity was assessed using thrombin-induced platelet-fibrin clot strength (TIP-FCS).
  • Lipid profiles were analyzed, and statin therapy effects were evaluated based on atorvastatin equivalent doses.

Main Results:

  • Statin therapy was associated with a dose-dependent reduction in urinary 11-dh TxB2 (p=0.046), independent of LDL and apo B100 levels.
  • Statin use was strongly correlated with reduced TIP-FCS (p=0.006), indicating decreased thrombogenicity.
  • Lack of statin therapy (p=0.0007) and female gender (p=0.007) were independently linked to higher urinary 11-dh TxB2 levels.

Conclusions:

  • Statin therapy in aspirin-treated CAD patients is independently associated with reduced inflammation in a dose-dependent manner.
  • Elevated urinary 11-dh TxB2 levels correlate with a prothrombotic state, as indicated by high TIP-FCS.
  • Urinary 11-dh TxB2 may serve as a valuable biomarker for optimizing statin dosage to mitigate thrombotic risk.

Keywords:
Aspirincoronary artery diseaseinflammationlipidsplateletsstatinurinary 11-dehydrothromboxane B2

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

7.7K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522